What makes more scientific sense: combining a CCR5 inhibitor (leronlimab) with a CCR8 inhibitor or a LAG3 inhibitor (eftilagimod alpha)? Address safety considerations.
I asked my google AI overview that question. She basically said CCR5 and CCR8 inhibition do similar things and might be redundant. Combining a LAG3 and CCR5 inhibitor offers complimentary MOAs. A bit long, but worth the read:
Based on current understanding of the tumor microenvironment (TME) and immune checkpoint mechanisms, combining a CCR5 inhibitor (leronlimab) with a LAG3 inhibitor (such as relatlimab or eftilagimod alpha) makes more scientific sense than combining leronlimab with a CCR8 inhibitor.
Combining CCR5 inhibition with LAG3 inhibition targets different, complementary mechanisms of immune suppression, whereas CCR5 and CCR8 both target trafficking/suppression by myeloid cells, potentially leading to redundant or less effective outcomes.
1. Scientific Rationale: Leronlimab + LAG3 Inhibitor
--Mechanism Synergy: Leronlimab (PRO 140) blocks the CCR5 receptor, reducing the migration of immunosuppressive myeloid-derived suppressor cells (MDSCs) and T regulatory cells (Tregs) into the tumor. LAG3 is an immune checkpoint receptor found on exhausted T cells that, when blocked, boosts T cell proliferation and cytokine production.
--Complementary Approach: Combining these two addresses both sides of the immunosuppressive equation:
--Leronlimab (Cold to Hot): Reduces the influx of suppressor cells (Tregs/MDSCs), transforming a "cold" (immune-resistant) tumor into a "hot" (immune-responsive) one.
--LAG3 Inhibitor (Unleashing T cells): Reverses T cell exhaustion, allowing the now-present T cells to actively kill tumor cells.
--Reversing Resistance: Studies indicate that high CCR5 expression correlates with increased LAG3 expression on T cells, suggesting that inhibiting CCR5 can complement LAG3 inhibition to reverse resistance to checkpoint inhibitors.
2. Comparison: Leronlimab + CCR8 Inhibitor
--Redundancy Concerns: CCR5 and CCR8 are both chemokine receptors involved in trafficking immunosuppressive cells (Tregs and myeloid cells) to the tumor. While both are valid targets, inhibiting both simultaneously may not provide the same synergistic, "two-pronged" attack (e.g., T-cell activation + traffic regulation) that adding a true immune checkpoint inhibitor like LAG3 offers.
--Functional Overlap: Both inhibitors would be primarily working to reduce the same type of cell trafficking, potentially leading to diminishing returns compared to combining different types of mechanisms.
3. Safety Considerations
--Leronlimab Safety Profile: Leronlimab has shown a favorable safety profile in multiple trials (HIV, COVID-19, oncology) with no major safety signals identified.
--LAG3 Inhibitor Safety: Combination therapies involving LAG3 (such as with anti-PD1) have shown manageable toxicity, generally having lower rates of severe, treatment-related adverse events compared to CTLA-4 inhibitors.
--Combination Safety: The combination of a CCR5 inhibitor and a LAG3 inhibitor is theoretically favorable. The major risk in combining immunotherapies is the increase in immune-related adverse events (irAEs). However, because these agents act on different mechanisms—one on tumor microenvironment modulation (CCR5) and one on T-cell activation (LAG3)—the toxicity profile is likely to be distinct and potentially more manageable than combining two different T-cell checkpoint inhibitors.
Data Support: Clinical trials are already investigating the combination of CCR5 inhibitors with other checkpoint blockades (such as ipilimumab and nivolumab), showing the validity of this approach.
Conclusion
Combining leronlimab (CCR5) + a LAG3 inhibitor is more scientifically compelling because it targets two distinct, non-redundant mechanisms of immune evasion (blocking trafficking and reversing T-cell exhaustion), which is likely to result in greater efficacy and a manageable safety profile compared to the more overlapping effects of combining two trafficking-related inhibitors.
I asked my google AI overview that question. She basically said CCR5 and CCR8 inhibition do similar things and might be redundant. Combining a LAG3 and CCR5 inhibitor offers complimentary MOAs. A bit long, but worth the read:
Based on current understanding of the tumor microenvironment (TME) and immune checkpoint mechanisms, combining a CCR5 inhibitor (leronlimab) with a LAG3 inhibitor (such as relatlimab or eftilagimod alpha) makes more scientific sense than combining leronlimab with a CCR8 inhibitor.
Combining CCR5 inhibition with LAG3 inhibition targets different, complementary mechanisms of immune suppression, whereas CCR5 and CCR8 both target trafficking/suppression by myeloid cells, potentially leading to redundant or less effective outcomes.
1. Scientific Rationale: Leronlimab + LAG3 Inhibitor
--Mechanism Synergy: Leronlimab (PRO 140) blocks the CCR5 receptor, reducing the migration of immunosuppressive myeloid-derived suppressor cells (MDSCs) and T regulatory cells (Tregs) into the tumor. LAG3 is an immune checkpoint receptor found on exhausted T cells that, when blocked, boosts T cell proliferation and cytokine production.
--Complementary Approach: Combining these two addresses both sides of the immunosuppressive equation:
--Leronlimab (Cold to Hot): Reduces the influx of suppressor cells (Tregs/MDSCs), transforming a "cold" (immune-resistant) tumor into a "hot" (immune-responsive) one.
--LAG3 Inhibitor (Unleashing T cells): Reverses T cell exhaustion, allowing the now-present T cells to actively kill tumor cells.
--Reversing Resistance: Studies indicate that high CCR5 expression correlates with increased LAG3 expression on T cells, suggesting that inhibiting CCR5 can complement LAG3 inhibition to reverse resistance to checkpoint inhibitors.
2. Comparison: Leronlimab + CCR8 Inhibitor
--Redundancy Concerns: CCR5 and CCR8 are both chemokine receptors involved in trafficking immunosuppressive cells (Tregs and myeloid cells) to the tumor. While both are valid targets, inhibiting both simultaneously may not provide the same synergistic, "two-pronged" attack (e.g., T-cell activation + traffic regulation) that adding a true immune checkpoint inhibitor like LAG3 offers.
--Functional Overlap: Both inhibitors would be primarily working to reduce the same type of cell trafficking, potentially leading to diminishing returns compared to combining different types of mechanisms.
3. Safety Considerations
--Leronlimab Safety Profile: Leronlimab has shown a favorable safety profile in multiple trials (HIV, COVID-19, oncology) with no major safety signals identified.
--LAG3 Inhibitor Safety: Combination therapies involving LAG3 (such as with anti-PD1) have shown manageable toxicity, generally having lower rates of severe, treatment-related adverse events compared to CTLA-4 inhibitors.
--Combination Safety: The combination of a CCR5 inhibitor and a LAG3 inhibitor is theoretically favorable. The major risk in combining immunotherapies is the increase in immune-related adverse events (irAEs). However, because these agents act on different mechanisms—one on tumor microenvironment modulation (CCR5) and one on T-cell activation (LAG3)—the toxicity profile is likely to be distinct and potentially more manageable than combining two different T-cell checkpoint inhibitors.
Data Support: Clinical trials are already investigating the combination of CCR5 inhibitors with other checkpoint blockades (such as ipilimumab and nivolumab), showing the validity of this approach.
Conclusion
Combining leronlimab (CCR5) + a LAG3 inhibitor is more scientifically compelling because it targets two distinct, non-redundant mechanisms of immune evasion (blocking trafficking and reversing T-cell exhaustion), which is likely to result in greater efficacy and a manageable safety profile compared to the more overlapping effects of combining two trafficking-related inhibitors.
5
